- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03280277
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
Novel Imaging of Lymph Nodes in Patients With Rectal Cancer Using Ferumoxytol Enhanced MRI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine feasibility of administering ferumoxytol and obtaining ferumoxytol enhanced magnetic resonance (MR) images in patients with resectable locally advanced rectal cancer with enlarged or suspicious lateral pelvic lymph nodes before starting neoadjuvant therapy and again before total mesorectal excision.
SECONDARY OBJECTIVES:
I. To collect detailed information about the location of ultrasmall superparamagnetic iron oxide (USPIO)-MRI detected lymph nodes prior to neoadjuvant therapy and again prior to total mesorectal excision.
II. To compare the sensitivity and specificity of ferumoxytol enhanced MR imaging in assessment of pathological lymph nodes with those of non-USPIO-MRI and positron emission tomography-computed tomography (PET-CT).
OUTLINE:
Patients receive ferumoxytol intravenously (IV) over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
After completion of study treatment, patients are followed up for 4-6 weeks.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- OHSU Knight Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically confirmed, locally advanced, malignancy of the rectum; based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatment
Stage T1-4bN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:
- CT chest/abdomen with contrast
- MRI pelvis with contrast
- PET/CT of the whole-body or skull base to mid-thigh
- Subjects must have had no prior therapy for cancer of the rectum
- Members of all races and ethnic groups will be included
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- White blood cell count >= 3.0 K/cu mm
- Absolute neutrophil count >= 1.5 K/cu mm
- Platelets >= 100 K/cu mm
- Hemoglobin >= 8.0 g/dl (the use of transfusion or other invention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
- Total bilirubin =< 1.5 X institutional upper limit of normal
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for subjects with creatinine levels above institutional normal
- Woman of childbearing potential, a negative serum or urine pregnancy test
- Willingness to use adequate contraception for 12 months after completion of all therapy
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Subjects with AJCC 7th edition stage TxN0 and/or metastatic disease outside of pelvis (suspicious lateral pelvic lymph nodes up to and including common iliacs are allowed on the protocol)
- Prior systemic chemotherapy for rectal cancer; prior chemotherapy for another malignancy is allowable as long as it has been > 2 years since completion of therapy for previous malignancy
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
- Prior abdominopelvic radiation or radiation for rectal cancer
- History of other malignancy in the past 2 years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma
- Medical contraindications to low anterior resection or abdominoperineal resection
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother, breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this study
- Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol
- Subjects with concurrent clinical diagnosis of evidence of active iron overload defined by the following 1) ferritin >= 250 ng/mL in men or >= 200 ng/mL in women AND 2) transferrin saturation, the ratio of plasma iron to transferrin, expressed as percent, >= 45%
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol
- Patients with renal insufficiency; glomerular filtration rate (GFR) < 60
- Adult patients who require monitored anesthesia for MRI scanning
- Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to gadolinium (Gd) contrast material
- Subjects with known hepatic insufficiency or cirrhosis as determined by either a prior diagnosing physician or at review at initial consultation; these disease entities do not have formal associated lab values and are thus a clinical diagnosis by the prior aforementioned physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Diagnostic (ferumoxytol-enhanced MRI)
Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
|
Given IV
Other Names:
Undergo ferumoxytol-enhanced MRI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Practical feasibility
Time Frame: Up to 6 weeks
|
Assessed by successful accrual objectively, as a percentage of all subjects enrolled.
Accrual success will be measured in binary fashion; successful accrual is considered a patient that enrolls and completes the entire trial.
All other eligible patients will be considered an accrual failure.
Practical feasibility will be considered a success if greater than 50%.
|
Up to 6 weeks
|
Technical feasibility of ultrasmall superparamagnetic iron oxide (USPIO) - magnetic resonance imaging (MRI) of the chest
Time Frame: Up to 6 weeks
|
Assessed by image quality and protocol completion.
Will be evaluated in a descriptive manner.
Image quality, readability (i.e. the ability for diagnostic radiologist to make an appropriate diagnostic conclusion), completion of ferumoxytol infusion, data acquisition, and completion of magnetic resonance protocol.
|
Up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reason for accrual failure
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
|
Report location and enhancement patterns on USPIO - MRI
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
|
Sensitivity and specificity of MRI imaging for all lymph nodes
Time Frame: Up to 6 weeks
|
Assessed by pathology finding.
Sensitivities and specificities of ferumoxytol enhanced MRI prior to neoadjuvant therapy will be calculated using pathology finding as the gold standard.
Each lymph node will be treated as an independent observation.
The sensitivity and specificity will be compared with those from positron emission tomography (PET)/computed tomography (CT) findings using McNemar's test.
Sensitivities and specificities of ferumoxytol enhanced MRI before surgery will also be calculated as a reference.
|
Up to 6 weeks
|
Sensitivity and specificity of PET/CT imaging
Time Frame: Up to 6 weeks
|
Assessed by pathology finding.
Sensitivities and specificities of ferumoxytol enhanced MRI prior to neoadjuvant therapy will be calculated using pathology finding as the gold standard.
Each lymph node will be treated as an independent observation.
The sensitivity and specificity will be compared with those from PET/CT findings using McNemar's test.
Sensitivities and specificities of ferumoxytol enhanced MRI before surgery will also be calculated as a reference.
|
Up to 6 weeks
|
Accuracy of USPIO - MRI
Time Frame: Up to 6 weeks
|
Accuracy, which is defined as the percentage of all patients or lymph nodes in which MRI with ferumoxytol correctly predicted the presence or absence of metastatic tumor, will be calculated.
|
Up to 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexander Guimaraes, OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Ferrosoferric Oxide
Other Study ID Numbers
- STUDY00016101 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2017-00388 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- ONC-16108-L
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage III Rectal Cancer AJCC v7
-
National Cancer Institute (NCI)Active, not recruitingStage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer AJCC v7 | Stage III Liver Cancer | Stage IV Liver Cancer | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon... and other conditionsUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)TerminatedMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein ProficientUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedLower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
National Cancer Institute (NCI)NRG OncologyCompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)CompletedRecurrent Rectal Carcinoma | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Rectal Mucinous Adenocarcinoma | Rectal Signet Ring Cell Adenocarcinoma | Stage IIA Rectal Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPancreatic Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Malignant Neoplasm | Recurrent Colorectal Carcinoma | Pancreatic Neuroendocrine Carcinoma | Malignant Head and Neck Neoplasm | Stage III Nasopharyngeal Carcinoma... and other conditionsUnited States
Clinical Trials on Ferumoxytol
-
Michael IvNational Cancer Institute (NCI)WithdrawnChildhood Brain NeoplasmUnited States
-
Allegheny Singer Research Institute (also known...Active, not recruitingLiver Neoplasms | Hepatocellular Carcinoma | Liver Metastases | Liver Cancer | Liver Carcinoma | Hepatocellular Cancer | Hepatic Cirrhosis | Hepatic Carcinoma | Hepatic AtrophyUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; National... and other collaboratorsRecruitingPancreatic Adenocarcinoma | Familial Pancreatic Cancer | Pancreatic Intraductal Papillary-Mucinous NeoplasmUnited States
-
Michael IvCompletedBrain Injury | Brain Cancer | Brain Tumors | Primary Brain Neoplasm | Ischemic Cerebrovascular Accident | Central Nervous System Degenerative Disorder | Central Nervous System Infectious Disorder | Central Nervous System Vascular Malformation | Hemorrhagic Cerebrovascular AccidentUnited States
-
Dana-Farber Cancer InstituteWithdrawn
-
AMAG Pharmaceuticals, Inc.UnknownPeripheral Arterial Disease (PAD)United States
-
National Cancer Institute (NCI)CompletedProstate CancerUnited States
-
University of EdinburghRoyal Brompton & Harefield NHS Foundation Trust; Royal Infirmary of Edinburgh; Golden Jubilee National HospitalCompletedMyocarditis | Healthy Volunteers | Cardiac Transplant | Cardiac SarcoidUnited Kingdom
-
Jason GagliaHarvard Medical School (HMS and HSDM); National Institute of Allergy and Infectious...Unknown